Cargando…

Quercetin abrogates chemoresistance in melanoma cells by modulating ΔNp73

BACKGROUND: The alkylating agent Dacarbazine (DTIC) has been used in the treatment of melanoma for decades, but when used as a monotherapy for cancer only moderate response rates are achieved. Recently, the clinical use of Temozolomide (TMZ) has become the more commonly used analog of DTIC-related o...

Descripción completa

Detalles Bibliográficos
Autores principales: Thangasamy, Thilakavathy, Sittadjody, Sivanandane, Mitchell, Geoffrey C, Mendoza, Erin E, Radhakrishnan, Vijayababu M, Limesand, Kirsten H, Burd, Randy
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895613/
https://www.ncbi.nlm.nih.gov/pubmed/20540768
http://dx.doi.org/10.1186/1471-2407-10-282
_version_ 1782183270224494592
author Thangasamy, Thilakavathy
Sittadjody, Sivanandane
Mitchell, Geoffrey C
Mendoza, Erin E
Radhakrishnan, Vijayababu M
Limesand, Kirsten H
Burd, Randy
author_facet Thangasamy, Thilakavathy
Sittadjody, Sivanandane
Mitchell, Geoffrey C
Mendoza, Erin E
Radhakrishnan, Vijayababu M
Limesand, Kirsten H
Burd, Randy
author_sort Thangasamy, Thilakavathy
collection PubMed
description BACKGROUND: The alkylating agent Dacarbazine (DTIC) has been used in the treatment of melanoma for decades, but when used as a monotherapy for cancer only moderate response rates are achieved. Recently, the clinical use of Temozolomide (TMZ) has become the more commonly used analog of DTIC-related oral agents because of its greater bioavailability and ability to cross the blood brain barrier. The response rates achieved by TMZ are also unsatisfactory, so there is great interest in identifying compounds that could be used in combination therapy. We have previously demonstrated that the bioflavonoid quercetin (Qct) promoted a p53-mediated response and sensitized melanoma to DTIC. Here we demonstrate that Qct also sensitizes cells to TMZ and propose a mechanism that involves the modulation of a truncated p53 family member, ΔNp73. METHODS: DB-1 melanoma (p53 wildtype), and SK Mel 28 (p53 mutant) cell lines were treated with TMZ (400 μM) for 48 hrs followed by Qct (75 μM) for 24 hrs. Cell death was determined by Annexin V-FITC staining and immunocytochemical analysis was carried out to determine protein translocation. RESULTS: After treatment with TMZ, DB-1 cells demonstrated increased phosphorylation of Ataxia telangiectasia mutated (ATM) and p53. However, the cells were resistant to TMZ-induced apoptosis and the resistance was associated with an increase in nuclear localization of ΔNp73. Qct treatment in combination with TMZ abolished drug insensitivity and caused a more than additive induction of apoptosis compared to either treatment alone. Treatment with Qct, caused redistribution of ΔNp73 into the cytoplasm and nucleus, which has been associated with increased p53 transcriptional activity. Knockdown of ΔNp73 restored PARP cleavage in the TMZ treated cells, confirming its anti-apoptotic role. The response to treatment was predominantly p53 mediated as the p53 mutant SK Mel 28 cells showed no significant enhancement of apoptosis. CONCLUSION: This study demonstrates that Qct can sensitize cells to TMZ and that the mechanisms of sensitization involve modulation of p53 family members.
format Text
id pubmed-2895613
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28956132010-07-02 Quercetin abrogates chemoresistance in melanoma cells by modulating ΔNp73 Thangasamy, Thilakavathy Sittadjody, Sivanandane Mitchell, Geoffrey C Mendoza, Erin E Radhakrishnan, Vijayababu M Limesand, Kirsten H Burd, Randy BMC Cancer Research Article BACKGROUND: The alkylating agent Dacarbazine (DTIC) has been used in the treatment of melanoma for decades, but when used as a monotherapy for cancer only moderate response rates are achieved. Recently, the clinical use of Temozolomide (TMZ) has become the more commonly used analog of DTIC-related oral agents because of its greater bioavailability and ability to cross the blood brain barrier. The response rates achieved by TMZ are also unsatisfactory, so there is great interest in identifying compounds that could be used in combination therapy. We have previously demonstrated that the bioflavonoid quercetin (Qct) promoted a p53-mediated response and sensitized melanoma to DTIC. Here we demonstrate that Qct also sensitizes cells to TMZ and propose a mechanism that involves the modulation of a truncated p53 family member, ΔNp73. METHODS: DB-1 melanoma (p53 wildtype), and SK Mel 28 (p53 mutant) cell lines were treated with TMZ (400 μM) for 48 hrs followed by Qct (75 μM) for 24 hrs. Cell death was determined by Annexin V-FITC staining and immunocytochemical analysis was carried out to determine protein translocation. RESULTS: After treatment with TMZ, DB-1 cells demonstrated increased phosphorylation of Ataxia telangiectasia mutated (ATM) and p53. However, the cells were resistant to TMZ-induced apoptosis and the resistance was associated with an increase in nuclear localization of ΔNp73. Qct treatment in combination with TMZ abolished drug insensitivity and caused a more than additive induction of apoptosis compared to either treatment alone. Treatment with Qct, caused redistribution of ΔNp73 into the cytoplasm and nucleus, which has been associated with increased p53 transcriptional activity. Knockdown of ΔNp73 restored PARP cleavage in the TMZ treated cells, confirming its anti-apoptotic role. The response to treatment was predominantly p53 mediated as the p53 mutant SK Mel 28 cells showed no significant enhancement of apoptosis. CONCLUSION: This study demonstrates that Qct can sensitize cells to TMZ and that the mechanisms of sensitization involve modulation of p53 family members. BioMed Central 2010-06-11 /pmc/articles/PMC2895613/ /pubmed/20540768 http://dx.doi.org/10.1186/1471-2407-10-282 Text en Copyright ©2010 Thangasamy et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Thangasamy, Thilakavathy
Sittadjody, Sivanandane
Mitchell, Geoffrey C
Mendoza, Erin E
Radhakrishnan, Vijayababu M
Limesand, Kirsten H
Burd, Randy
Quercetin abrogates chemoresistance in melanoma cells by modulating ΔNp73
title Quercetin abrogates chemoresistance in melanoma cells by modulating ΔNp73
title_full Quercetin abrogates chemoresistance in melanoma cells by modulating ΔNp73
title_fullStr Quercetin abrogates chemoresistance in melanoma cells by modulating ΔNp73
title_full_unstemmed Quercetin abrogates chemoresistance in melanoma cells by modulating ΔNp73
title_short Quercetin abrogates chemoresistance in melanoma cells by modulating ΔNp73
title_sort quercetin abrogates chemoresistance in melanoma cells by modulating δnp73
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895613/
https://www.ncbi.nlm.nih.gov/pubmed/20540768
http://dx.doi.org/10.1186/1471-2407-10-282
work_keys_str_mv AT thangasamythilakavathy quercetinabrogateschemoresistanceinmelanomacellsbymodulatingdnp73
AT sittadjodysivanandane quercetinabrogateschemoresistanceinmelanomacellsbymodulatingdnp73
AT mitchellgeoffreyc quercetinabrogateschemoresistanceinmelanomacellsbymodulatingdnp73
AT mendozaerine quercetinabrogateschemoresistanceinmelanomacellsbymodulatingdnp73
AT radhakrishnanvijayababum quercetinabrogateschemoresistanceinmelanomacellsbymodulatingdnp73
AT limesandkirstenh quercetinabrogateschemoresistanceinmelanomacellsbymodulatingdnp73
AT burdrandy quercetinabrogateschemoresistanceinmelanomacellsbymodulatingdnp73